Circulating Sclerostin levels and bone turnover in type 1 and type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 5, 2012, Pages 1737-1744

  Gennari, Luigi ^a   Merlotti, Daniela ^a   Valenti, Roberto ^a   Ceccarelli, Elena ^a   Ruvio, Martina ^a   Pietrini, Maria G ^a   Capodarca, Cosimo ^a   Franci, Maria Beatrice ^a   Campagna, Maria Stella ^a   Calabrò, Anna ^a   Cataldo, Dorica ^a   Stolakis, Konstantinos ^a   Dotta, Francesco ^a   Nuti, Ranuccio ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; PARATHYROID HORMONE; SCLEROSTIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; BONE TURNOVER; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; ENZYME ACTIVITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; BONE AND BONES; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; SEX FACTORS; VITAMIN D;

EID: 84860714853     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2958     Document Type: Article

References (44)

1. Vestergaard P 2007 Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta-analysis. Osteoporos Int 18:427-444
2. Maurer MS, Burcham J, Cheng H 2005 Diabetes mellitus is associated with an increased risk of falls in elderly residents of a longterm care facility. J Gerontol A Biol Sci Med Sci 60:1157-1162
3. Hofbauer LC, Brueck CC, Singh SK, Dobnig H 2007 Osteoporosis in Patients With Diabetes Mellitus J Bone Miner Res 22:1317-1328
4. Merlotti D, Gennari L, Dotta F, Lauro D, Nuti R 2010 Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutr Metab Cardiovasc Dis 20:683-690
5. Zayzafoon M, Stell C, Irwin R, McCabe LR 2000 Extracellular glucose influences osteoblast differentiation and c-Jun. expression. J Cell Biochem 79:301-310
6. McCabe LR 2007 Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem 102:1343-1357
7. Manolagas SC, Almeida M 2007 Gone with the Wnts: β-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol 21:2605-2614
8. Räkel A, Sheehy O, Rahme E, Le Lorier J 2008 Osteoporosis among patients with type 1 and type 2 diabetes. Diabetes Metab 34:193-205
9. Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM 1995 Bone loss and bone turnover in diabetes. Diabetes 44:775-782
10. Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL 2010 Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87:99-107
11. Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, Smith SY, Stolina M, Lacey DL, Simonet WS, Paszty C, Li G, Ke HZ 2011 Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 26:1012-1021
12. Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, Ominsky MS, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ 2010 Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 25:2647-2656
13. Papapoulos SE 2011 Targeting sclerostin as potential treatment of osteoporosis. Ann Rheum Dis 70(Suppl 1):i119-i122
14. Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton 3rd LJ, Khosla S 2011 Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 26:373-379
15. Kirmani S, Amin S, McCready LK, Atkinson EJ, Melton 3rd LJ, Müller R, Khosla S 2012 Sclerostin levels during growth in children. Osteoporos Int 23:1123-1130
16. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA 2010 Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95:1991-1997
17. Drake MT, Srinivasan B, Mödder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S 2010 Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95:5056-5062
18. Mödder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S 2011 Regulation of circulating sclerostin levels by sex steroids in women and men. J Bone Miner Res 26:27-34
19. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE 2010 Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 95:2248-2253
20. KDOQI 2007 KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 49(2 Suppl 2):S12-S154
21. Gonnelli S, Caffarelli C, Tanzilli L, Merlotti D, Gennari L, Rossi S, Lucani B, Campagna MS, Franci B, Nuti R 2011 The association of body composition and sex hormones with quantitative ultrasound parameters at the calcaneus and phalanxes in elderly women. Calcif Tissue Int 89:456-463
22. Gonnelli S, Caffarelli C, Del Santo K, Cadirni A, Guerriero C, Lucani B, Franci B, Nuti R 2008 The relation ship of ghrelin and adiponectin with bone mineral density and bone turnover markers in elderly men. Calcif Tissue Int 83:55-60
23. Takiishi T, Gysemans C, Bouillon R, Mathieu C 2010 Vitamin D and diabetes. Endocrinol Metab Clin North Am 39:419-446
24. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D 2005 Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883-19887
25. Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Latham JA 2004 Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 35:828-835
26. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CW 2004 Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805-814.
27. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP 2002 High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1521
28. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, Fitz Gerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, et al. 2002 A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11-19
29. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, et al. 2001 LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523
30. Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E 2012 Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide. Osteoporos Int 23:1171-1176
31. Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH 2011 Determinants of serum sclerostin in healthy pre-and postmenopausal women. J Bone Miner Res 26:2812-2822
32. Wergedal JE, Veskovic K, Hellan M, Nyght C, Balemans W, Libanati C, Vanhoenacker FM, Tan J, Baylink DJ, Van Hul W 2003 Patients with van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab 88:5778-5783
33. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T 2008 Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One 3:e2942
34. Padhi D, Jang G, Stouch B, Fang L, Posvar E 2011 Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19-26
35. Kramer I, Keller H, Leupin O, Kneissel M 2010 Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol Metab 21:237-244
36. Keller H, Kneissel M 2005 SOST is a target gene for PTH in bone. Bone 37:148-158
37. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL 2005 Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577-4583
38. van Lierop AH, Witteveen JE, Hamdy NA, Papapoulos SE 2010 Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol 163:833-837
39. Kaji H, Imanishi Y, Sugimoto T, Seino S 2011 Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia. Exp Clin Endocrinol Diabetes 119:440-444
40. Costa AG, Cremers S, Rubin MR, McMahon DJ, Sliney J Jr., Lazaretti-Castro M, Silverberg Jr S, Bilezikian JP 2011 Circulating sclerostin in disorders of parathyroid gland function. J Clin Endocrinol Metab 96:3804-3810
41. Yu EW, Kumbhani R, Siwila-Sackman E, Leder BZ 2011 Acute Decline in Serum Sclerostin in Response to PTH Infusion in Healthy Men. J Clin Endocrinol Metab 96:E1848-E1851
42. Andress DL, Hercz G, Kopp JB, Endres DB, Norris KC, Coburn JW, Sherrard DJ 1987 Bone histomorphometry of renal osteodystrophy in diabetic patients. J Bone Miner Res 2:525-531
43. Yoshida O, Inaba M, Terada M, Shioi A, Nishizawa Y, Otani S, Morii H 1995 Impaired response of human osteosarcoma (MG-63) cells to human parathyroid hormone induced by sustained exposure to high glucose. Miner Electrolyte Metab 21:201-204
44. Suzuki K, Miyakoshi N, Tsuchida T, Kasukawa Y, Sato K, Itoi E 2003 Effects of combined treatment of insulin and human parathyroid hormone (1-34) oncancellous bone mass and structure in streptozotocin-induced diabetic rats. Bone 33:108-114